Angiographic regression of cardiac allograft vasculopathy after introducing sirolimus immunosuppression
- 1 November 2003
- journal article
- case report
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 22 (11) , 1276-1279
- https://doi.org/10.1016/s1053-2498(02)01239-1
Abstract
No abstract availableKeywords
This publication has 19 references indexed in Scilit:
- Impact of everolimus on allograft vasculopathy the SDZ Rad/heart intravascular ultrasound studyThe Journal of Heart and Lung Transplantation, 2002
- Safety and efficacy of everolimus (RAD) as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: six-month analysisThe Journal of Heart and Lung Transplantation, 2002
- Bench to BedsideCirculation, 2001
- INCIDENCE, PROGRESSION AND FUNCTIONAL SIGNIFICANCE OF CARDIAC ALLOGRAFT VASCULOPATHY AFTER HEART TRANSPLANTATION1Transplantation, 2000
- Rapamycin inhibits vascular smooth muscle cell migration.Journal of Clinical Investigation, 1996
- Early development of accelerated graft coronary artery disease: Risk factors and courseJournal of the American College of Cardiology, 1996
- RAPAMYCIN INHIBITS TRANSPLANT VASCULOPATHY IN LONG-SURVIVING RAT HEART ALLOGRAFTSTransplantation, 1995
- Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle CellsCirculation Research, 1995
- EFFECTS OF RAPAMYCIN ON GROWTH FACTOR-STIMULATED VASCULAR SMOOTH MUSCLE CELL DNA SYNTHESIS INHIBITION OF BASIC FIBROBLAST GROWTH FACTOR AND PLATELET-DERIVED GROWTH FACTOR ACTION AND ANTAGONISM OF RAPAMYCIN BY FK506Transplantation, 1995
- Effects of cyclosporin, FK506, and rapamycin on graft-vessel diseaseThe Lancet, 1991